Recruiting NCT06541860

DAratumumab and REvlimid REfractory MM

— Observational Multiple Myeloma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to: Registry conditions: Multiple Myeloma. Basic parameters: from 18 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Italy
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience

Overview

Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.

Primary outcome measures

To explore the efficacy and tolerability of different combinations, particularly the PVD regimen, in the emerging context of RRMM after anti-CD38 MoAb plus IMIDS therapy. [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

Phase I

Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
Patients aged ≥ 18 years
Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Phase II

Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
Patients aged ≥ 18 years
Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Exclusion criteria

Patients not willing to consent to review of clinical data

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model: Cohort

Study locations

Italy · 1 center

Irccs San Matteo Pavia — Pavia

Identifiers

NCT: NCT06541860 · DARE-MM

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗